Lv41
470 积分 2024-03-03 加入
Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?
1小时前
待确认
Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia
2小时前
已完结
Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group
5天前
已完结
Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin ( NPM1 ) gene mutation subtypes: a single-center experience and review of the literature
6天前
已完结
Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML
28天前
已关闭
TP53-Mutated Acute Myeloid Leukemia: How Can We Improve Outcomes?
2个月前
已关闭
Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)
2个月前
已完结
Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203
2个月前
已完结
High incidence of CALM-AF10 fusion and the identification of a novel fusion transcript in acute megakaryoblastic leukemia in children without Down's syndrome
2个月前
已完结
Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias
2个月前
已完结
皖公网安备34019202002308
